To develop human ACE2 transgenic mice in strains that express all classes of human FcγRs to study the mechanisms of antibody-mediated protection against Covid-19 infection.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Jeffrey RavetchResearch Location
United States of AmericaLead Research Institution
The Rockefeller UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable